Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer

According to a Prognoscan database, upregulation of Bruton's tyrosine kinase (Btk) is associated with low overall survival in ovarian cancer patients. We found that spheroids-forming ovarian cancer cell, which highly expressed cancer stem-like cell (CSC) markers and Btk, were cisplatin resistan...

Descripción completa

Detalles Bibliográficos
Autores principales: Zucha, Muhammad Ary, Wu, Alexander T.H., Lee, Wei-Hwa, Wang, Liang-Shun, Lin, Wan-Wan, Yuan, Chiou-Chung, Yeh, Chi-Tai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4537012/
https://www.ncbi.nlm.nih.gov/pubmed/26036311
_version_ 1782385831620640768
author Zucha, Muhammad Ary
Wu, Alexander T.H.
Lee, Wei-Hwa
Wang, Liang-Shun
Lin, Wan-Wan
Yuan, Chiou-Chung
Yeh, Chi-Tai
author_facet Zucha, Muhammad Ary
Wu, Alexander T.H.
Lee, Wei-Hwa
Wang, Liang-Shun
Lin, Wan-Wan
Yuan, Chiou-Chung
Yeh, Chi-Tai
author_sort Zucha, Muhammad Ary
collection PubMed
description According to a Prognoscan database, upregulation of Bruton's tyrosine kinase (Btk) is associated with low overall survival in ovarian cancer patients. We found that spheroids-forming ovarian cancer cell, which highly expressed cancer stem-like cell (CSC) markers and Btk, were cisplatin resistant. We next treated CSCs and non-CSCs by a combination of ibrutinib and cisplatin. We found that chemoresistance was dependent on Btk and JAK2/STAT3, which maintained CSC by inducing Sox-2 and prosurvival genes. We suggest that addition of ibrutinib to cisplatin may improve treatment outcome in ovarian cancer.
format Online
Article
Text
id pubmed-4537012
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-45370122015-08-26 Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer Zucha, Muhammad Ary Wu, Alexander T.H. Lee, Wei-Hwa Wang, Liang-Shun Lin, Wan-Wan Yuan, Chiou-Chung Yeh, Chi-Tai Oncotarget Research Paper According to a Prognoscan database, upregulation of Bruton's tyrosine kinase (Btk) is associated with low overall survival in ovarian cancer patients. We found that spheroids-forming ovarian cancer cell, which highly expressed cancer stem-like cell (CSC) markers and Btk, were cisplatin resistant. We next treated CSCs and non-CSCs by a combination of ibrutinib and cisplatin. We found that chemoresistance was dependent on Btk and JAK2/STAT3, which maintained CSC by inducing Sox-2 and prosurvival genes. We suggest that addition of ibrutinib to cisplatin may improve treatment outcome in ovarian cancer. Impact Journals LLC 2015-03-26 /pmc/articles/PMC4537012/ /pubmed/26036311 Text en Copyright: © 2015 Zucha et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Zucha, Muhammad Ary
Wu, Alexander T.H.
Lee, Wei-Hwa
Wang, Liang-Shun
Lin, Wan-Wan
Yuan, Chiou-Chung
Yeh, Chi-Tai
Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer
title Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer
title_full Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer
title_fullStr Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer
title_full_unstemmed Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer
title_short Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer
title_sort bruton's tyrosine kinase (btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4537012/
https://www.ncbi.nlm.nih.gov/pubmed/26036311
work_keys_str_mv AT zuchamuhammadary brutonstyrosinekinasebtkinhibitoribrutinibsuppressesstemliketraitsinovariancancer
AT wualexanderth brutonstyrosinekinasebtkinhibitoribrutinibsuppressesstemliketraitsinovariancancer
AT leeweihwa brutonstyrosinekinasebtkinhibitoribrutinibsuppressesstemliketraitsinovariancancer
AT wangliangshun brutonstyrosinekinasebtkinhibitoribrutinibsuppressesstemliketraitsinovariancancer
AT linwanwan brutonstyrosinekinasebtkinhibitoribrutinibsuppressesstemliketraitsinovariancancer
AT yuanchiouchung brutonstyrosinekinasebtkinhibitoribrutinibsuppressesstemliketraitsinovariancancer
AT yehchitai brutonstyrosinekinasebtkinhibitoribrutinibsuppressesstemliketraitsinovariancancer

Ejemplares similares